Covid-19 and Unaccounted Collateral Damage

Dr Metzler and collaborators carried out a retrospective search to find out the impact of the Covid-19 pandemic on diagnosis and treatment of acute coronary syndromes during March 2020 in Austria. Basically, they tried to account for the collateral damage we all imagine, but no government reports. 

COVID-19 y el daño colateral que nadie contabiliza

During March we observed a significant drop in the number of ACS patients admitted to the emergency rooms. This drop is close to 40% and is even bigger when it comes to Non-STEMI patients.

It came as a surprise to the authors, who had speculated with an increase in the number of cases, according to their experience with other viral infections, natural disasters, or profound financial crisis. We could say Covid-19 is a combination of all three.

The strict health care protocols that undoubtedly helped and keep helping to control this pandemic might have unintentionally affected the attention paid to other diseases. 


Read also: Special Articles on COVID-19.


ACS symptoms such as dyspnea and chest discomfort might easily be mistaken for acute respiratory infections. 

In addition, strict instructions to stay at home and fear of catching the disease might have caused many patients to avoid hospitals despite clearly manifesting symptoms. 

Regardless possible reasons and speculations, the smaller number of patients being treated will eventually translate into increased early and late cardiovascular mortality. This is the unaccounted, and therefore unreported, death toll no government will address.


Read also: Cardiovascular Sequelae Associated with COVID-19.


Compared against similar periods in a pre-pandemic context, and considering  1950 MI mortality rates (times we had nothing to offer, just like the present context, with untreated CAD patients undergoing an ACS at home) we can easily assume there have been 110 unaccounted ACS deaths during March alone for a population of 8.8 million people, such as Austria’s.

The government of Austria has informed 86 deaths due to coronavirus in this same month. However, collateral damage from the virus protocols can be worse yet than the virus itself. 

Original Title: Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage.

Reference: Bernhard Metzler et al. European Heart Journal (2020) 41, 1852–1853. doi:10.1093/eurheartj/ehaa314.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...